Four AI Misconceptions That Put Your Clinical Trial at Risk
From regulatory exposure to enrollment bias, these common assumptions about AI in trials can derail programs and inflate costs. · An FDA Warning Letter in…
Trial Watch posts – July 2026
Public Trial Watch posts from July 2026, newest first. Each heading links to the post.
Why Single-Task AI Tools Miss the Real Problem in Clinical…
Protocol amendments and deviations are system failures, not isolated task errors. Your AI strategy needs to match. · Phase III protocols now average 5.96…
Protocol Amendments: The Hidden Multimillion-Dollar Drain…
New data shows amendment timelines have tripled in a decade, with 76% of trials now requiring changes that cost sponsors up to eight figures per program. ·…
AI Orchestration: Managing Clinical Documents as a…
How multi-agent AI systems can reduce amendment burden and maintain cross-document consistency throughout the trial lifecycle · Every protocol amendment…
The Clinical Trial Document Dependency Map: How Documents…
Why a protocol amendment at Month 6 triggers a cascade of updates across ICF, SAP, IB, and training materials. · A protocol amendment rarely stands alone. By…
Romania Is an Emerging EU Clinical Trial Market With…
Large patient access, EU regulatory alignment and a 30 day silent approval pathway make Romania one of Eastern Europe’s most interesting research markets. ·…
Clinical Trials as Treatment Access: What Sites Need to Know
How trial design, geography, and regulatory pathways shape patient access to investigational therapies · For many patients with advanced disease or rare…
AI Regulatory Writing: What It Means for Clinical Trial…
Large language models are entering the regulatory writing workflow, but human oversight remains critical for protocol accuracy and compliance. · Every…
Why Nearly All Protocols Still Need Amendments, and What…
A Hemex CRO executive's observation stopped the room: nearly every protocol she's worked on required amendments. Here's what that costs, and what changes. ·…
Hungary Is an Experienced Clinical Trial Hub in Central…
Strong investigator depth, predictable EU regulation and Budapest anchored site infrastructure make Hungary a high value market for sponsors. · Hungary is a…
Why Clinical Trials Are Graphs, Not Timelines
Understanding the dependency structure behind trial delays, site activation bottlenecks, and protocol amendments · Most teams think of trials as timelines…
Czech Republic Is a Fast and Precise Clinical Trial Market…
Compact geography, fast EU approvals, strong oncology infrastructure and reliable recruitment make Czech Republic a high value clinical research destination…
Poland Is One of Central Europe’s Strongest Clinical Trial…
Scale, EU aligned regulation, experienced sites and strong patient access make Poland a major research destination for global sponsors. · Poland has become…
Trial Watch: Edition 12
Where conviction is building in clinical development, in real time. · Trial Watch Edition 12 captures high signal clinical development activity from June 16…
Oncology enters a sharper phase of legacy standard…
From GIST to CLL and DLL3 driven tumors, oncology programs are moving into direct tests against established treatment standards. · Oncology is one of the…
The ROI Case for AI Regulatory Document Generation
Regulatory writing is no longer only a documentation function. It is becoming a timeline, cost and decision quality lever. · Clinical trial documentation is…
Trial Watch: Edition 11
Where conviction is building in clinical development, in real time. · Trial Watch Edition 11 captures high signal clinical development activity from June 1 to…
Phase 2 Protocol Design Is Where Development Risk Starts…
A stronger Phase 2 protocol can reduce downstream uncertainty before a program moves toward Phase 3. · Phase 2 is where clinical development starts facing…